HIF-1α modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms

Mini-Reviews in Medicinal Chemistry

Volumn 9, Issue 9, 2009, Pages 1084-1101

  Marín Hernández, Alvaro ^a   Gallardo Pérez, Juan C ^a   Ralph, Stephen J ^b   Rodríguez Enríquez, Sara ^a   Moreno Sánchez, Rafael ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

^b GRIFFITH UNIVERSITY   (Australia)

Author keywords

Glucose transporters; Glycolysis; Glycolytic inhibitors; Hexokinases; HIF 1 ; Mitochondria; Mitochondrial inhibitors

Indexed keywords

6 PHOSPHOFRUCTO 2 KINASE; 6 PHOSPHOFRUCTOKINASE; ANTINEOPLASTIC AGENT; CLOTRIMAZOLE; CYTOCHROME C OXIDASE; DEOXYGLUCOSE; DIGOXIN; ENOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE; GLUCOSE 6 PHOSPHATE ISOMERASE; GLUCOSE TRANSPORTER; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; GOSSYPOL; HEXOKINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; KONINGIC ACID; LACTATE DEHYDROGENASE; MANASSANTIN B; MITOCHONDRIAL ENZYME; MONOCARBOXYLATE TRANSPORTER; OXALIC ACID; OXAMIC ACID; PHOSPHOGLYCERATE KINASE; PHOSPHOGLYCERATE MUTASE; PYRUVATE DEHYDROGENASE; PYRUVATE KINASE; TOPOTECAN; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ISOPROTEIN;

ADRENAL CORTEX CARCINOMA; ADRENAL TUMOR; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CARCINOGENESIS; CELL HYPOXIA; CLINICAL TRIAL; DRUG CYTOTOXICITY; DRUG STRUCTURE; DRUG TARGETING; EHRLICH ASCITES TUMOR; ENERGY METABOLISM; ENZYME ACTIVITY; GLIOMA; GLYCOLYSIS; HUMAN; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; METABOLIC REGULATION; MITOCHONDRIAL RESPIRATION; NONHUMAN; OSTEOSARCOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; ANIMAL; DRUG ANTAGONISM; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; NEOPLASM;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOLYSIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; NEOPLASMS; PROTEIN ISOFORMS;

EID: 70349570410     PISSN: 13895575     EISSN: None     Source Type: Journal    
DOI: 10.2174/138955709788922610     Document Type: Review

References (166)

1. Knowles, H.J.; Harris, A.L. Hypoxia and oxidative stress in breast cancer. Hypoxia and tumourigenesis. Breast Cancer Res., 2001, 3, 318-322
2. Lu, C.W.; Lin, S.C.; Chen, K.F.; Lai, Y.Y.; Tsai, S.J. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J. Biol. Chem., 2008, 283, 28106-28114
3. Weidemann, A.; Johnson, R.S. Biology of HIF-1alpha. Cell Death Differ., 2008, 15, 621-627
4. Semenza, G.L; Roth, P.H.; Fang, H.M.; Wang, G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia -inducible factor 1. J. Biol. Chem., 1994, 269, 23757-63,
5. Denko, N. C. Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat. Rev. Cancer, 2008, 8, 705-713
6. Kim, J.W.; Gao, P.; Dang, C.V. Effects of hypoxia on tumor metabolism. Cancer Metastasis Rev., 2007, 26, 291-298
7. Lisy, K; Peet, D.J. Turn me on: regulating HIF transcriptional activity. Cell Death Differ., 2008, 15, 642-649
8. Huang L.E.; Gu, J.; Schau, M.; Bunn, H.F. Regulation of hypoxiainducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA, 1998, 95, 7987-7992 (Pubitemid 28326053)
9. Zhong, H,; De Marzo, A.M.; Laughner, E; Lim, M.; Hilton, D.A.; Zagzag, D.; Buechler, P.; Isaacs, W.; Semenza, G.L.; Simons, J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res., 1999, 59, 5830-5835
10. Lundgren, K.; Holm, C.; Landberg, G. Hypoxia and breast cancer: prognostic and therapeutic implications. Cell Mol. Life Sci., 2007, 64, 3233-3247
11. Sun, H.L.; Liu, Y.N.; Huang, Y.T.; Pan, S.L.; Huang, D.Y.; Guh, J.H.; Lee, F.Y.; Kuo, S.C.; Teng, C.M. YC-1 inhibits HIF-1 expression in prostate cancer cells: contribution of Akt/NF-kappaB signaling to HIF-1alpha accumulation during hypoxia. Oncogene, 2007, 26, 3941-3951
12. Shyu, K.G.; Hsu, F.L.; Wang, M.J.; Wang, B.W.; Lin, S. Hypoxiainducible factor 1alpha regulates lung adenocarcinoma cell invasion. Exp. Cell. Res., 2007, 313, 1181-1191 (Pubitemid 46437248)
13. Talks, K.L.; Turley, H.; Gatter, K.C.; Maxwell, P.H.; Pugh, C.W.; Ratcliffe, P.J.; Harris, A.L. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol., 2000, 157, 411-421
14. Monsef, N.; Helczynski, L.; Lundwall, A.; Pahlman, S.; Anders- Bjartell . Localization of immunoreactive HIF-1alpha and HIF- 2alpha in neuroendocrine cells of both benign and malignant prostate glands. Prostate, 2007, 67, 1219-1229
15. Vaupel, P.; Mayer, A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev., 2007, 26, 225-239
16. Fong, G.H.; Takeda, K. Role and regulation of prolyl hydroxylase domain proteins. Cell Death Differ., 2008, 15, 635-641
17. Ward, J.P. Oxygen sensors in context. Biochim. Biophys. Acta, 2008, 1777, 1-14.
18. Koivunen, P.; Hirsilä, M.; Kivirikko, K.I.; Myllyharju, J. The length of peptide substrates has a marked effect on hydroxylation by the hypoxia-inducible factor prolyl 4-hydroxylases. J. Biol. Chem., 2006, 281, 28712-28720 (Pubitemid 44507013)
19. Ehrismann, D.; Flashman, E.; Genn, D.N.; Mathioudakis, N.; Hewitson, K.S., Ratcliffe, P.J.; Schofield, C.J. Studies on the activity of the hypoxia-inducible-factor hydroxylases using an oxygen consumption assay. Biochem. J., 2007, 401, 227-234
20. Tsai, A.G.; Johnson, P.C.; Intaglieta, M. Is the distribution of tissue pO(2) homogeneous? Antioxid. Redox Signal., 2007, 9, 979-984
21. Cabrales, P.; Tsai, A.G.; Frangos, J.A.; Intaglieta, M. Role of endothelial nitric oxide in microvascular oxygen delivery and consumption. Free Radic. Biol. Med., 2005, 39, 1229-1237 (Pubitemid 41407715)
22. Lee, K.; Roth, R.A.; LaPres, J.J. Hypoxia, drug therapy and toxicity. Pharmacol. Ther., 2007, 113, 229-246
23. Fandrey, J.; Gorr, T.A.; Gassmann, M. Regulating cellular oxygen sensing by hydroxylation. Cardiovasc. Res., 2006, 71, 642-651 (Pubitemid 44848002)
24. Appelhoff, R.J.; Tian, Y.M.; Raval, R.R.; Turley, H.; Harris, A.L.; Pugh, C.W.; Ratcliffe, P.J.; Gleadle, J.M. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem., 2004, 279, 38458-38465
25. Stiehl, D.P.; Wirthner, R.; Köditz, J.; Spielmann, P.; Camenisch, G.; Wenger, R.H. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. Evidence for an autoregulatory oxygen-sensing system. J. Biol. Chem., 2006, 281, 23482-23491 (Pubitemid 44274123)
26. Klimova, T.; Chandel, N.S. Mitochondrial complex III regulates hypoxic activation of HIF. Cell Death Differ., 2008, 15, 660-666
27. Taylor, C.T. Mitochondria and cellular oxygen sensing in the HIF pathway. Biochem J., 2008, 409, 19-26.
28. Covian, R.; Pardo, J.P.; Moreno-Sánchez, R. Tight binding of inhibitors to bovine bc1 complex is independent of the Rieske protein redox state. Consequences for semiquinone stabilization in the quinol oxidation site. J. Biol. Chem., 2002, 277, 48449-48455 (Pubitemid 35470803)
29. Pouysségur, J.; Mechta-Grigoriou, F. Redox regulation of the hypoxia- inducible factor. Biol. Chem., 2006, 387, 1337-1346 (Pubitemid 44691412)
30. Bell, E.L.; Klimova, T.A.; Eisenbart, J.; Moraes, C.T.; Murphy, M.P.; Budinger, G.R.S.; Chandel, N.S. The Qo site of the mitochondrial complex III is required for the transduction of hypoxic signaling via reactive oxygen species production. J. Cell Biol., 2007, 177, 1029-1036.
31. Horvat, S.; Beyer, C.; Arnold, S. Effect of hypoxia on the transcription pattern of subunit isoforms and the kinetics of cytochrome c oxidase in cortical astrocytes and cerebellar neurons. J. Neurochem., 2006, 99, 937-951 (Pubitemid 44583451)
32. Neuzil, J.; Dyason, J.C.; Freeman, R.; Dong, L. F.; Prochazka, L.; Wang, X. F.; Scheffler, I.; Ralph, S.J. Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. J. Bioenerg. Biomembr., 2007, 39, 65-72. (Pubitemid 46877173)
33. Pitkanen, S.; Robinson, B.H. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. J. Clin. Invest., 1996, 98, 345-351
34. Dong, L.F.; Freeman, R.; Liu, J.; Zobalova, R.; Marín- Hernández, A.; Stantic, M.; Rohlena, J.; Rodríguez- Enríquez, S.; Valis, K.; Butcher, B.; Goodwin, J.; Brunk, U.T.; Witting, P.K.; Moreno- Sánchez, R.; Scheffler, I.E.; Ralph, S.J.; Neuzil, J. Suppression of tumor growth in vivo by the mitocan alpha-tocopheryl succinate requires respiratory complex II. Clin. Cancer. Res., 2009, 15, 1593-1600
35. Habelhah, H.; Laine, A.; Erdjument-Bromage, H.; Tempst, P.; Gershwin, M.E.; Bowtell, D.D.; Ronai, Z. Regulation of 2- oxoglutarate (alpha-ketoglutarate) dehydrogenase stability by the RING finger ubiquitin ligase Siah. J. Biol. Chem., 2004, 279, 53782-53788 (Pubitemid 40051887)
36. Li, X.F.; Carlin, S.; Urano, M.; Russell, J.; Ling, C.C.; O'Donoghue, J.A. Visualization of hypoxia in microscopic tumors by immunofluorescent microscopy. Cancer Res., 2007, 67, 7646-7653
37. Leo, C.; Horn, L.C.; Einenkel, J.; Hentschel, B.; Höckel, M. Tumor hypoxia and expression of c-met in cervical cancer. Gynecol. Oncol., 2007, 104, 181-185 (Pubitemid 46054122)
38. Liao, D.; Johnson, R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev., 2007, 26, 281-290
39. Bonicalzi, M.E.; Groulx, I.; Paulsen, N.; Lee, S. Role of exon 2- encoded beta -domain of the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem., 2001, 276, 1407-1416 (Pubitemid 32096572)
40. Lu, H.; Dalgard, C.L.; Mohyeldin, A.; McFate, T.; Tait, A.S.; Varma, A. Reversible inactivation of HIF-1 prolyl hydroxylases allows cell metabolism to control basal HIF-1. J. Biol. Chem., 2005, 280, 41928-41939
41. Selak, M.A.; Armour S.M.; MacKenzie, E.D.; Boulahbel, H.; Watson, D.G.; Mansfield, K.D.; Pan, Y.; Simon, M.C.; Thompson, C.B.; Gottlieb, E. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 2005, 7, 77-85. (Pubitemid 40126384)
42. Pollard, P.J.; Brière, J.J.; Alam, N.A.; Barwell, J.; Barclay, E.; Wortham, N.C.; Hunt, T.; Mitchell, M.; Olpin, S.; Moat, S.J.; Hargreaves, I.P.; Heales, S.J.; Chung, Y.L.; Griffiths, J.R.; Dalgleish, A.; McGrath, J.A.; Gleeson, M.J.; Hodgson, S.V.; Poulsom, R.; Rustin, P.; Tomlinson, I.P. Accumulation of Krebs cycle intermediates and over-expression of HIF1alpha in tumours which result from germline FH and SDH mutations. Hum. Mol. Genet., 2005, 14, 2231-2239 (Pubitemid 41418022)
43. Lee, S.; Nakamura, E.; Yang, H.; Wei, W.; Linggi, M.S.; Sajan, M.P.; Farese, R.V.; Freeman, R.S.; Carter, B.D.; Kaelin, W.G. Jr.; Schlisio, S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell, 2005, 8, 155-167 (Pubitemid 41132744)
44. Rankin, E.B.; Giaccia, A.J. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ., 2008, 15, 678-685
45. Patel, S.A.; Simon, M.C. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ., 2008, 15, 628-634
46. Jang, M.S.; Park, J.E.; Lee, J.A.; Park, S.G.; Myung, P.K.; Lee, D.H.; Park, B.C.; Cho, S. Binding and regulation of hypoxiainducible factor-1 by the inhibitory PAS proteins. Biochem. Biophys. Res. Commun., 2005, 337, 209-215 (Pubitemid 41393781)
47. Zhong, H.; Hanrahan, C.; van der Poel, H.; Simona, J.W. Hypoxiainducible factor 1alpha and 1beta proteins share common signaling pathways in human prostate cancer cells. Biochem. Biophys. Res. Commun., 2001, 284, 352-356
48. Pedersen, P.L. Mitochondrial events in the life and death of animal cells: a brief overview. J. Bioenerg. Biomembr., 1999, 31, 291-304.
49. Moreno-Sánchez, R.; Rodríguez-Enríquez, S.; Marín-Hernández, A.; Saavedra, E. Energy metabolism in tumor cells. FEBS J., 2007, 274, 1393-1418
50. Takahashi, Y.; Takahashi, S.; Yoshimi, T.; Miura, T. Hypoxiainduced expression of phosphoglycerate mutase B in fibroblasts. Eur. J. Biochem., 1998, 254, 497-504. (Pubitemid 28308099)
51. Gess, B.; Hofbauer, K.H.; Deutzmann, R.; Kurtz, A. Hypoxia up-regulates triosephosphate isomerase expression via a HIF-dependent pathway. Pflugers Arch., 2004, 448, 175-180 (Pubitemid 38648177)
52. Ullah, M.S.; Davies, A.J.; Halestrap, A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J. Biol. Chem. 2006, 281, 9030-9037
53. Obach, M.; Navarro-Sabate, A.; Caro, J.; Kong, X.; Duran, J.; Gómez, M.; Perales, J.C.; Ventura, F.; Rosa, J.L.; Bartrons, R. 6- Phosphofructo-2-kinase (pfkfb3) gene promoter contains hypoxiainducible factor-1 binding sites necessary for transactivation in response to hypoxia. J. Biol. Chem., 2004, 279, 53562-53570 (Pubitemid 40051863)
54. Funasaka, T.; Yanagawa, T.; Hogan, V.; Raz, A. Regulation of phosphoglucose isomerase/autocrine motility factor expression by hypoxia. FASEB J., 2005, 19, 1422-1430 (Pubitemid 41279000)
55. Macheda, M.L.; Rogers, S.; Best, J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol., 2005, 202, 654-662
56. Pessino, A.; Hebert, D.N.; Woon, C.W.; Harrison, S.A.; Clancy, B.M.; Buxton, J.M.; Carruthers, A.; Czech, M.P. Evidence that functional erythrocyte-type glucose transporters are oligomers. J. Biol. Chem., 1991, 266, 20213-20217
57. Zhao, F.Q.; Keating, A.F. Functional properties and genomics of glucose transporters. Curr. Genomics, 2007, 8, 113-128
58. Burant, C.F.; Bell, G.I. Mammalian facilitative glucose transporters: evidence for similar substrate recognition sites in functionally monomeric proteins. Biochemistry, 1992, 31, 10414-10420
59. Gould, G.W.; Thomas, H.M.; Jess, T.J.; Bell, G.I. Expression of human glucose transporters in Xenopus oocytes: kinetic characterization and substrate specificities of the erythrocyte, liver, and brain isoforms. Biochemistry, 1991, 30, 5139-5145
60. Liu, Q.; Vera, J.C.; Peng, H.; Golde, H. The predicted ATP-binding domains in the hexose transporter GLUT1 critically affect transporter activity. Biochemistry, 2001, 40, 7874-7881
61. Alterberg, B.; Greulich, K.O. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Genomics, 2004, 84, 1014-1020
62. Marín-Hernández, A.; Rodríguez-Enríquez, S.; Vital-González, P.A.; Flores-Rodríguez, F.L.; Macías-Silva, M.; Sosa-Garrocho, M.; Moreno-Sánchez, R. Determining and understanding the control of glycolysis in fast-growth tumor cells. Flux control by an over-expressed but strongly product-inhibited hexokinase. FEBS J. 2006, 273, 1975-1988
63. Wilson, J.E. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J. Exp. Biol., 2003, 206, 2049-2057
64. Pedersen, P.L.; Mathupala, S.; Rempel, A.; Geschwind, J.F.; Ko, Y.H. Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. Biochim. Biophys. Acta, 2002, 1555, 14-20.
65. Xie, G.; Wilson, J.E. Tetrameric structure of mitochondrially bound rat brain hexokinase: a crosslinking study. Arch. Biochem. Biophys., 1990, 276, 285-293 (Pubitemid 20041847)
66. Pastorino, J.G.; Shulga, N.; Hoek, J.B. Mitochondrial binding of hexokinase II inhibits Bax-induced cytochrome c release and apoptosis. J. Biol. Chem., 2002, 277, 7610-7618 (Pubitemid 34953160)
67. Majewski, N.; Nogueira, V.; Robey, R.B.; Hay, N. Akt inhibits apoptosis downstream of BID cleavage via a glucose-dependent mechanism involving mitochondrial hexokinases. Mol. Cell. Biol., 2004, 24, 730-740 (Pubitemid 38057924)
68. Machida, K.; Ohta, Y.; Osada, H. Suppression of apoptosis by cyclophilin D via stabilization of hexokinase II mitochondrial binding in cancer cells. J. Biol. Chem., 2006, 281, 14314-14320 (Pubitemid 43848360)
69. Nakashima, R.; Paggi, M.; Scott, L.J.; Pedersen, P.L. Purification and characterization of a bindable form of mitochondrial bound hexokinase from the highly glycolytic AS-30D rat hepatoma cell line. Cancer Res., 1988, 48, 913-919
70. Ardehali, H.; Printz, R.L.; Koch, S.; Whitesell, R.R.; May, J.M.; Granner, D.K. Functional interaction between the N- and Cterminal halves of human hexokinase II. J. Biol. Chem., 1999, 274, 15986-15989 (Pubitemid 129526340)
71. White, T.K.; Wilson, J.E. Rat brain hexokinase: location of the allosteric regulatory site in a structural domain at the N-terminus of the enzyme. Arch. Biochem. Biophys., 1987, 259, 402-411
72. Radojkovic, J.; Ureta, T. Hexokinase isoenzymes from the Novikoff hepatoma. Purification, kinetic and structural characterization, with emphasis on hexokinase C. Biochem. J., 1987, 242, 895-903. (Pubitemid 17049510)
73. Ko, Y.H.; Pedersen, P.L.; Geschwind, J.F. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett., 2001, 173, 83-91.
74. Ko, Y.H.; Smith, B.L.; Wang, Y.; Pomper, M.G.; Rini, D.A.; Torbenson, M.S.; Hullihen, J.; Pedersen, P.L. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem. Biophys. Res. Commun., 2004, 324, 269-275
75. Xu, R.; Pelicano, H.; Zhou, Y.; Carew, J.S.; Feng, L.; Bhalla, K.N.; Keating, M.J.; Huang, P. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res., 2005, 65, 613-621
76. Jones, A.R.; Gillan, L.; Milmlow, D. The anti-glycolytic activity of 3-bromopyruvate on mature boar spermatozoa in vitro. Contraception, 1995, 52, 317-320
77. Pereira da Silva, A.P.; El-Bacha, T.; Kyaw, N.; dos Santos, R.S.; da-Silva, W.S.; Almeida, F.C.; Da Poian A.T.; Galina, A. Inhibition of energy-producing pathways of HepG2 cells by 3- bromopyruvate. Biochem. J., 2009, 417, 717-726
78. Penso, J.; Beitner, R. Detachment of glycolytic enzymes from cytoskeleton of Lewis lung carcinoma and colon adenocarcinoma cells induced by clotrimazole and its correlation to cell viability and morphology. Mol. Genet. Metab., 2002, 76, 181-188 (Pubitemid 35034550)
79. Meira, D.D.; Marinho-Carvalho, M.M.; Teixeira, C.A.; Veiga, V.F.; Da Poian, A.T.; Holandino, C.; de Freitas, M.S.; Sola-Penna, M. Clotrimazole decreases human breast cancer cells viability through alterations in cytoskeleton-associated glycolytic enzymes. Mol. Genet. Metab., 2005, 84, 354-362 (Pubitemid 40386883)
80. Khalid, M.H.; Tokunaga, Y.; Caputy, A. J.; Walters, E. Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. J. Neurosurg., 2005, 103, 79-86. (Pubitemid 43193938)
81. van Wijk, R.; van Solinge, W.W. The energy-less red blood cell is lost: erythrocyte enzyme abnormalities of glycolysis. Blood, 2005, 106, 4034-4042
82. Kim, J.W.; Dang, C.V. Multifaceted roles of glycolytic enzymes. Trends Biochem. Sci., 2005, 30, 142-150
83. Chirgwin, J.M.; Parsons, T.F.; Noltmann, E.A. Mechanistic implications of the pH independence of inhibition of phosphoglucose isomerase by neutral sugar phosphates. J. Biol. Chem., 1975, 250, 7277-7279
84. Reitzer, L.J.; Wice, B.M.; Kennell, D. The pentose cycle. Control and essential function in HeLa cell nucleic acid synthesis. J. Biol. Chem., 1980, 255, 5616-5626
85. Horton, R.W.; Meldrum, B.S.; Bachelard, H.S. Enzymic and cerebral metabolic effects of 2-deoxy-D-glucose. J. Neurochem., 1973, 21, 507-520
86. 3H]glucose conversion into 3HOH in rat erythrocytes. Biochem. J. 1992, 288, 433-438
87. Liu, H.; Hu, Y.P.; Savaraj, N.; Priebe, W.; Lampidis, T.J. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry, 2001, 40, 5542-5547 (Pubitemid 32458256)
88. Maschek, G.; Savaraj, N.; Pruebe, W.; Braunschweiger, P.; Hamilton, K.; Tudmarsh, G.F.; De Young, L.R.; Lampidis, T.J. 2-deoxy- D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res., 2004, 64, 31-34
89. Dwarakanath, B.S.; Khaitan, D.; Ravindranath, T. 2-deoxy-Dglucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines. Cancer Biol. Ther., 2004, 3, 864-870 (Pubitemid 41351053)
90. Gupta, S.; Mathur, R.; Dwarakanath, B.S. The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in Ehrlich ascites tumor-bearing mice. Cancer Biol. Ther., 2005, 4, 87-94.
91. Kang, H.T.; Hwang, E.S. 2-Deoxyglucose: an anticancer and antiviral therapeutic, but not any more a low glucose mimetic. Life Sci., 2006, 78, 1392-1399
92. Lynch, R.M.; Fogarty, K.E.; Fay, F.S. Modulation of hexokinase association with mitochondria analyzed with quantitative threedimensional confocal microscopy. J. Cell Biol., 1991, 112, 385-395
93. Dunaway, G.A.; Kasten, T.P.; Sebo, T.; Trapo, R. Analysis of the phosphofructokinase subunits and isoenzymes in human tissues. Biochem. J., 1988, 251, 677-683 (Pubitemid 18121401)
94. Rodríguez-Enríquez, S.; Juárez, O.; Rodríguez-Zavala, J.S.; Moreno- Sánchez, R. Multisite control of the Crabtree effect in ascites hepatoma cells. Eur. J. Biochem., 2001, 268, 2512-2519 (Pubitemid 32417780)
95. González-Mateos, F.; Gómez, M.E.; García-Salguero, L.; Sánchez, V.; Aragón, J.J. Inhibition of glycolysis by amino acids in ascites tumor cells. Specificity and mechanism. J. Biol. Chem., 1993, 268, 7809-7817 (Pubitemid 23120355)
96. Denis, C.; Paris, H.; Murat, J.C. Hormonal control of fructose 2,6- bisphosphate concentration in the HT29 human colon adenocarcinoma cell line. Alpha 2-adrenergic agonists counteract effect of vasoactive intestinal peptide. Biochem. J., 1986, 239, 531-536
97. Loiseau, A.M.; Rousseau, G.G.; Hue, L. Fructose 2,6-bisphosphate and the control of glycolysis by glucocorticoids and by other agents in rat hepatoma cells. Cancer Res., 1985, 45, 4263-4269 (Pubitemid 16224884)
98. Pezza, J.A.; Choi, K.H.; Berardini, T.Z.; Beernink, P.T.; Allen, K.N.; Tolan, D.R. Spatial clustering of isozyme-specific residues reveals unlikely determinants of isozyme specificity in fructose- 1,6-bisphosphate aldolase. J. Biol. Chem., 2003, 278, 17307-17313
99. Biswas, S.; Ray, M.; Misra, S.; Dutta, D.P.; Ray, S. Selective inhibition of mitochondrial respiration and glycolysis in human leukaemic leucocytes by methylglyoxal. Biochem. J., 1997, 323, 343-348 (Pubitemid 27183114)
100. Sirover, M.A. Role of the glycolytic protein, glyceraldehyde-3- phosphate dehydrogenase, in normal cell function and in cell pathology. J. Cell Biochem., 1997, 66, 133-140
101. Welch, J.E.; Brown, P.L.; O'Brien, D.A.; Magyar, P.L.; Bunch, D.O.; Mori, C.; Eddy, E. M. Human glyceraldehydes 3-phosphate dehydrogenase-2 gene is expressed specifically in spermatogenic cells. J. Androl., 2000, 21, 328-338
102. Jaroszewski, J.W.; Kaplan, O.; Cohen, J.S. Action of gossypol and rhodamine 123 on wild type and multidrug-resistant MCF-7 human breast cancer cells: 31P nuclear magnetic resonance and toxicity studies. Cancer Res., 1990, 50, 6936-6943
103. Tuszynski, G.P.; Cossu, G. Differential cytotoxic effect of gossypol on human melanoma, colon carcinoma, and other tissue culture cell lines. Cancer Res., 1984, 44, 768-771 (Pubitemid 14184616)
104. Oliver, C.L.; Miranda, M.B.; Shangary, S.; Land, S.; Wang, S.; Johnson, D.E. (-)-Gossypol acts directly on the mitochondria to overcome Bcl-2- and Bcl-X(L)-mediated apoptosis resistance. Mol. Cancer Ther., 2005, 4, 23-31.
105. Wu, Y.W.; Chik, C.L.; Knazek, R.A. An in vitro and in vivo study of antitumor effects of gossypol on human SW-13 adrenocortical carcinoma. Cancer Res., 1989, 49, 3754-3758
106. Bushunow, P.; Reidenberg, M.M.; Wasenko, J.; Lorenzo, B.; Lemke, S.; Himpler, B.; Corona, R.; Coyle, T. Gossypol treatment of recurrent adult malignant gliomas. J. Neurooncol., 1999, 43, 79-86. (Pubitemid 29351981)
107. Sakai, K.; Hasumi, K.; Endo, A. Inactivation of rabbit muscle glyceraldehyde- 3-phosphate dehydrogenase by koningic acid. BBA-Prot. Struct. Mol. Enzymol., 1988, 952, 297-303 (Pubitemid 18051023)
108. Kumagai, S.; Narasaki, R,; Hasumi, K. Glucosa-dependent active ATP depletion by koningic acid kills high-glycolytic cells. Biochem. Biophys. Res. Commun., 2008, 365, 362-368 (Pubitemid 350137298)
109. Ralph, S.J. Arsenic-based antineoplastic drugs and their mechanisms of action. Metal Based Drugs., 2008, 2008, Article ID 260146.
110. Lay, A.J.; Jiang, X.M.; Kisker, O.; Flynn, E.; Underwood, A.; Condron, R.; Hogg, P.J. Phosphoglycerate kinase acts in tumour angiogenesis as a disulphide reductase. Nature, 2000, 408, 869-873
111. Repiso, A.; Ramirez-Bajo, M.J.; Vives-Corrons, J.L.; Carreras, J.; Climent, F. Phosphoglycerate mutase BB isoenzyme deficiency in a patient with non-spherocytic anemia: familial and metabolic studies. Haematologica, 2005, 90, 257-259 (Pubitemid 40293291)
112. Fundele, R.; Krietsch, W.K. Purification and properties of the phosphoglycerate mutase isozymes from the mouse. Comp. Biochem. Physiol. B., 1985, 81, 965-968
113. Durany, N.; Joseph, J.; Campo, E.; Molina, R.; Carreras, J. Phosphoglycerate mutase, 2,3 bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas. Br. J. Cancer, 1997, 75, 969-977 (Pubitemid 27122614)
114. Durany, N.; Joseph, J.; Jimenez, O.M.; Climent, F.; Fernández, P.L.; Rivera, F.; Carreras, J. Phosphoglycerate mutase, 2,3- bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma. Br. J. Cancer, 2000, 82, 20-27 (Pubitemid 30008953)
115. Kondoh, H.; Lleonart, M.E.; Gil, J.; Wang, J.; Degan, P.; Peters, G.; Martinez, D.; Carnero, A.; Beach, D. Glycolytic enzymes can modulate cellular life span. Cancer Res., 2005, 65, 177-185 (Pubitemid 40070808)
116. Pancholi, V. Multifunctional alpha-enolase: its role in diseases. Cell. Mol. Life Sci., 2001, 58, 902-920 (Pubitemid 32652817)
117. Shimizu, A.; Suzuki, F.; Kato, K. Characterization of alpha alpha, beta beta, gamma gamma and alpha gamma human enolase isozymes, and preparation of hybrid enolases (alpha gamma, beta gamma and alpha beta) from homodimeric forms. BBA-Prot. Struct. Mol. Enzymol., 1983, 748, 278-284 (Pubitemid 14240272)
118. Imamura, K.; Tanaka, T. Pyruvate kinase isozymes from rat. Methods Enzymol., 1982, 90, 150-165
119. Mazurek, S.; Grimm, H.; Boschek, C.B.; Vaupel, P.; Eigenbrodt, E. Pyruvate kinase type M2: a crossroad in the tumor metabolome. Brit. J. Nutr., 2002, 87, S23-9. (Pubitemid 34134101)
120. Christofk, H.R.; Vander-Heiden, M.G.; Wu, N.; Asara, J.M.; Cantley, L.C. Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature, 2008, 452, 181-186
121. Drent, M.; Cobben, N.A.; Henderson, R.F.; Wouters, E.F.M.; van Dieijen-Visser, M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur. Respir. J., 1996, 9, 1736-1742
122. Buhl, S.N.; Jackson, K.Y.; Vanderlinde, R.E. The effect of temperature on the kinetic constants of human lactate dehydrogenase 1 and 5. Clin. Chim. Acta, 1977, 80, 265-270
123. Koukourakis, M.I.; Giatromanolaki, A.; Simopoulos, C.; Polychronidis, A.; Sivridis, E. Lactate dehydrogenase 5 (LDH5) relates to up-regulated hypoxia inducible factor pathway and metastasis in colorectal cancer. Clin. Exp. Metastasis, 2005, 22, 25-30. (Pubitemid 41185858)
124. Elwood, J.C. Effect of oxamate on glycolysis and respiration in sarcoma 37 ascites cells. Cancer Res., 1968, 28, 2056-2060
125. Jow, G.M.; Wu, Y.C.;Guh, J.H.; Teng, C.M. Armepavine oxalate induces cell death on CCRF-CEM leukemia cell line through an apoptotic pathway. Life Sci., 2004, 75, 549-557
126. Görlach, A.; Acker, H. pO2- and pH-gradients in multicellular spheroids and their relationship to cellular metabolism and radiation sensitivity of malignant human tumor cells. BBA-Mol. Basis Dis., 1994, 1227, 105-112 (Pubitemid 24371737)
127. Martin-Requero, A.; Ayuso, M.S.; Parrilla, R. Rate-limiting steps for hepatic gluconeogenesis. Mechanism of oxamate inhibition of mitochondrial pyruvate metabolism. J. Biol. Chem., 1986, 261, 13973-13978
128. Beutler, E.; Forman, L.; West, C. Effect of oxalate and malonate on red cell metabolism. Blood, 1987, 70, 1389-1393 (Pubitemid 18026143)
129. Fantin, V.R.; St-Pierre, J.; Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell, 2006, 9, 425-434 (Pubitemid 43832190)
130. Okar, D.A.; Manzano, A.; Navarro-Sabate, A.; Riera, L.l.; Bartrons, R.; Lange, A.J. PFK-2/FBPase-2: maker and breaker of the essential biofactor fructose-2,6-bisphosphate. Trends Biochem. Sci., 2001, 26, 30-35
131. Halestrap, A.P.; Meredith, D. The SLC16 gene family-from monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch., 2004, 447, 619-628 (Pubitemid 38241446)
132. Izumi, H.; Torigoe, T.; Ishiguchi, H.; Yoshida, Y.; Tanabe, M.; Ise, T.; Murakami, T.; Yoshida, T.; Nomoto, M.; Kohno, K. Cellular pH regulators: potentially promising molecular targets for cancer chemotherapy. Cancer Treat. Rev., 2003, 29, 541-549 (Pubitemid 37428326)
133. Gallagher, S.M.; Castorino, J.J.; Wang, D.; Philp, N.J. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res., 2007, 67, 4182-4189
134. Martín-Venegas, R.; Rodríguez-Lagunas, M.J.; Geraert, P.A.; Ferrer, R. Monocarboxylate transporter 1 mediates DL-2-Hydroxy-(4- methylthio)butanoic acid transport across the apical membrane of Caco-2 cell monolayers. J. Nutr., 2007, 137, 49-54. (Pubitemid 46052858)
135. Sonveaux, P.; Végran, F.; Schroeder, T.;Wergin, M.C. ; Verrax, J.; Rabbani, Z.N.; De Saedeleer, C.J.; Kennedy, K.M; Diepart, C.; Jordan, B.F.; Kelley, M.J.; Gallez, B.; Wahl, M.L.; Feron, O.; Dewhirst, M.W. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest., 2008,118, 3930-3942
136. Bowman, E.J.; Bowman, B.J. V-ATPases as drug targets. J. Bioenerg. Biomembr., 2005, 37, 431-435
137. Gerweck, L.E.; Vijayappa, S.; Kozin, S. Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol. Cancer Ther., 2006, 5, 1275-1279 (Pubitemid 43881320)
138. Sennoune, S.R.; Luo, D.; Martinez-Zaguilan, R. Plasmalemmal vacuolar-type H+-ATPase in cancer biology. Cell Biochem. Biophys., 2004, 40, 185-206. (Pubitemid 41270787)
139. Bowman, E.J.; Gustafson, K.R.; Bowman, B.J.; Boyd, M.R. Identification of a new chondropsin class of antitumor compound that selectively inhibits V-ATPases. J. Biol. Chem., 2003, 278, 44147-44152
140. Lu, X.; Qin, W.; Li, J.; Tan, N.; Pan, D.; Zhang, H.; Xie, L.; Yao, G.; Shu, H.; Yao, M.; Wan, D.; Gu, J.; Yang, S. The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res., 2005, 65, 6843-6849 (Pubitemid 41060723)
141. Fukuda, R.; Zhang, H.; Kim, J.W.; Shimoda, L.; Dang, C.V.; Semenza, G.L. HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. Cell, 2007, 129, 111-122
142. Campian, J.L.; Gao, X.; Qian, M.; Eaton, J.W. Cytochrome c oxidase activity and oxygen tolerance. J. Biol. Chem., 2007, 282, 12430-12438
143. Moreno-Sánchez, R.; Saavedra, E.; Rodríguez- Enríquez, S.; Olín- Sandoval, V. Metabolic control analysis: a tool for designing strategies to manipulate metabolic pathways. J. Biomed. Biotechnol., 2008, 2008, Article ID 597913.
144. Roche, T.E.; Hiromasa, Y. Pyruvate dehydrogenase kinase regulatory mechanisms and inhibition in treating diabetes, heart ischemia, and cancer. Cell Mol. Life Sci., 2007, 64, 830-849 (Pubitemid 46597752)
145. Gudi, R.; Bowker-Kinley, M.M.; Kedishvili, N.Y.; Zhao, Y.; Popov, K. Diversity of the pyruvate dehydrogenase kinase gene family in humans. J. Biol. Chem., 1995, 270, 28989-28994
146. Bowker-Kinley, M.M.; Davis, W.I.; Wu, P.; Harris, R.A.; Popov, K.M. Evidence for existence of tissue-specific regulation of the mammalian pyruvate dehydrogenase complex. Biochem. J., 1998, 329, 191-196 (Pubitemid 28022308)
147. Korotchkina, L.G.; Patel, M.S. Site specificity of four pyruvate dehydrogenase kinase isoenzymes toward the three phosphorylation sites of human pyruvate dehydrogenase. J. Biol. Chem., 2001, 276, 37223-37229 (Pubitemid 37384139)
148. Kolobova, E.; Tuganova, A.; Boulatnikov, I.; Popov, K.M. Regulation of pyruvate dehydrogenase activity through phosphorylation at multiple sites. Biochem. J., 2001, 358, 69-77. (Pubitemid 32778099)
149. Papandreou, I.; Cairns, R.A.; Fontana, L.; Lim, A.L.; Denko, N.C. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab., 2006, 3, 187-197
150. Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1- mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab., 2006, 3, 177-185
151. McFate, T.; Mohyeldin, A.; Lu, H.; Thakar, J.; Henriques, J.; Halim, N.D.; Wu, H.; Schell, M.J.; Tsang, T.M.; Teahan, O.; Zhou, S.; Califano, J.A.; Jeoung, N.H.; Harris, R.A.;Verma, A. Pyruvate dehydrogenase complex activity controls metabolic and malignant phenotype in cancer cells. J. Biol. Chem., 2008, 283, 22700-22708
152. Bonnet, S.; Archer, S.L.; Allalunis-Turner, J.; Haromy, A.; Beaulieu, C.; Thompson, R.; Lee, C.T.; Lopaschuk, G.D.; Puttagunta, L.; Bonnet, S.; Harry, G.; Hashimoto, K.; Porter, C.J.; Andrade, M.A.; Thebaud, B.; Michelakis E.D. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell, 2007, 11, 37-51.
153. Martínez-Sánchez, G.; Giuliani, A. Cellular redox status regulates hypoxia inducible factor-1 activity. Role in tumour development. J. Exp. Clin. Cancer Res., 2007, 26, 39-50. (Pubitemid 46656031)
154. Hossain, C.F.; Kim, Y.P.; Baerson, S.R.; Zhang, L.; Bruick, R.K.; Mohammed, K.A.; Agarwal, A.K.; Nagle, D.G.; Zhou, Y.D. Saururus cernuus lignans-potent small molecule inhibitors of hypoxia-inducible factor-1. Biochem. Biophys. Res. Commun., 2005, 333, 1026-1033
155. Zhang, H.; Qian, D.Z.; Tan, Y.S.; Lee, K.; Gao, P.; Ren, Y.R.; Rey, S.; Hammers, H.; Chang, D.; Pili, R.; Dang, C.V.; Liu, J.O.; Semenza, G.L. Digoxin and other cardiac glycosides inhibit HIF- 1alpha synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA, 2008, 105, 19579-19586
156. Kong, D.; Park, E.J.; Stephen, A.G.; Calvani, M.; Cardellina, J.H.; Monks, A.; Fisher, R.J.; Shoemaker, R.H.; Melillo, G. Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity. Cancer Res., 2005, 65, 9047-9055 (Pubitemid 41377397)
157. Takahashi, Y.; Nishikawa, M.; Takakura, Y. Inhibition of tumor cell growth in the liver by RNA interference-mediated suppression of HIF-1alpha expression in tumor cells and hepatocytes. Gene Ther., 2008, 15, 572-582
158. Choi, H.J.; Eun, J.S.; Kim, B.G.; Kim, S.Y.; Jeon, H.; Soh, Y. Vitexin, an HIF-1alpha inhibitor, has anti-metastatic potential in PC12 cells. Mol. Cells, 2006, 22, 291-299
159. Puppo, M.; Battaglia, F., Ottaviano, C.; Delfino, S.; Ribatti, D.; Varesio, L.; Bosco, M.C. Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor- 1alpha and -2alpha. Mol. Cancer Ther., 2008, 7, 1974-1984
160. Carmeliet, P.; Dor, Y.; Herbert, J.M.; Fukumura, D.; Brusselmans, K.; Dewerchin, M.; Neeman, M.; Bono, F.; Abramovitch, R.; Maxwell, P.; Koch, C.J.; Ratcliffe, P.; Moons, L.; Jain, R.K.; Collen, D.; Keshert, E. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature, 1998, 394, 485-490 (Pubitemid 28373960)
161. Blouw, B,; Song, H.; Tihan, T.; Bosze, J.; Ferrara, N.; Gerber, H.P.; Johnson, R.S.; Bergers G. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell, 2003, 4, 133-146 (Pubitemid 37040829)
162. Ameln, H.; Gustafsson, T.; Sundberg, C.J.; Okamoto, K.; Jansson, E,; Poellinger, L.; Makino, Y. Physiological activation of hypoxia inducible factor-1 in human skeletal muscle. FASEB J., 2005, 19, 1009-1011 (Pubitemid 40827734)
163. Critchley, H.O.; Osei, J.; Henderson, T.A.; Boswell, L.; Sales, K.J.; Jabbour, H.N.; Hiranio, N. Hypoxia-inducible factor-1alpha expression in human endometrium and its regulation by prostaglandin Eseries prostanoid receptor 2 (EP2). Endocrinology, 2006, 147, 744-753
164. Neuzil, J., Zhao, M., Ostermann, G., Sticha, M., Gellert, N., Weber, C., Eaton, J.W., Brunk, U.T. Alpha-tocopheryl succinate, an agent with in vivo anti-tumour activity, induces apoptosis by causing lysosomal instability. Biochem. J., 2002, 362, 709-715 (Pubitemid 34242323)
165. Balinsky, D.; Platz, C.E.; Lewis, J.W. Isozyme patterns of normal, benign, and malignant human breast tissues. Cancer Res., 1983, 43, 5895-5901
166. Atsumi, T.; Chesney, J.; Metz, A.; Leng, L.; Donnelly, S.; Makita, Z.; Mitchell, R.; Bucala, R. High expression of inducible 6-phosphofructo- 2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res., 2002, 62, 5881-5887 (Pubitemid 35204749)